September 21, 2021
Antifibrotics may extend lives for patients with IPF
Mayo Clinic researchers recently learned that patients who are taking antifibrotic drugs for idiopathic pulmonary fibrosis (IPF) have a better chance of survival after a respiratory-related hospitalization compared to patients not receiving these medications. The study, which was supported by Three Lakes Foundation, was published recently in BMC Pulmonary Medicine. Read Three Lakes news release. […]
Tags: Andrew Limper, Center for the Science of Health Care Delivery, idiopathic pulmonary fibrosis, OptumLabs
August 23, 2021
Mayo Clinic Research in the news — 8/23/2021
By Advancing the Science contributor
In the last 15 days or so, COVID-19 related news continues to dominate the headlines on the research front. However, Mayo Clinic’s expertise also was evident on topics from inclusivity in clinical trials, a geological connection in kidney stones, life extending therapies and better understanding of contributors to dementia, stroke and death. Read on for […]
Tags: brain, clinical trials, cognitive impairment, COVID-19, dementia, diversity, health disparities, hypertension, idiopathic pulmonary fibrosis, immune system, kidney stones, knee replacement
September 20, 2019
Good news about the effectiveness of antifibrotics for IPF
In a recent study published in the American Journal of Respiratory and Critical Care, a research team led by Andrew Limper, M.D., a pulmonology and critical care physician at Mayo Clinic, evaluated the effectiveness of pirfenidone and nintedanib for patients with idiopathic pulmonary fibrosis. The researchers reported “the medications had an association with a reduced […]
Tags: Andrew Limper, Center for the Science of Health Care Delivery, clinical trials, idiopathic pulmonary fibrosis, OptumLabs